Projects per year
Personal profile
Biography
Professor Andrew Wei is a Victorian Cancer Agency Research Fellow and Haematologist at the Alfred Hospital. Andrew conducts clinical and translational AML research through dual appointments at the Alfred Hospital and Monash University.
After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, he joined the Alfred Hospital in 2008 to develop the AML research program. He has been the AML disease group chairperson for Australasian Leukaemia and Lymphoma Group since 2009 and has led multiple nationwide cooperative group studies as chief investigator. His doctoral research studies contributed to discoveries elucidating the functional interaction between Bcl-2 family members (Molecular Cell 2005;17(3):393-403), the role of Mcl-1 in cancer susceptibility to ABT-737 (Cancer Cell. 2006;10(5):389-99) and the pro-survival function of the EBV Bcl-2 homologue BHRF-1 (PLoS Pathogens 2010;6[12]).
Professor Wei is an executive member of the ALLG Scientific Advisory Committee, a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia and Head of Leukaemia Research at the Alfred hospital. He sits on the International Steering Committee for Celgene providing expert advice on AML. To enhance translational research, Dr Wei has established the Alfred Haematology Tissue Bank, the diagnostic molecular haematology laboratory and a pre-clinical research laboratory to focus on the role of targeting survival pathways in AML.
Related Links:
- Australian Centre For Blood Diseases, Leukaemia Research Group Leader http://www.acbd.monash.org/research/leukaemia-tr-group.html
- Professional Profile www.acbd.monash.org/staff/wei.html
Research interests
Dr. Wei's research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Wei's laboratory seeks to identify new therapeutic targets in leukaemia.
Projects:
- Targetting 'survival kinases' in leukemic stem and progenitor cells
- The role of inositol phosphatases in regulating normal and malignant hemopoiesis
- Human models of AML
Monash teaching commitment
2007 - Present : Adjunct senior lecturer
Clinical activities
Investigator initiated AML trail funding:
- Phase 1 study of RAD001 and low dose ara-C for elderly AML
- Phase 1 study of azacitidine and lenalidomide as maintenance therapy in AML
- Phase 1 study of azacitidine and everolimus in relapsed AML
- Phase 1 multicentre ALLG study of lenalidomide maintenance therapy in AML
- Phase 2 randomised controlled multicentre ALLG study of Sorafenib in FLT3-ITD AML
- Phase 2 randomised multicentre ALLG study of high-dose lenalidomide and azacitidine and depsipeptide in relapsed AML
Cooperative Group Studies Local Site PI:
- Phase 3 study: ALLG AML M12 study
- Phase 2 study: ALLG APML M4 study
- Phase 2/3: UK MRC16 AML study
Company sponsored studies as local site PI:
- Phase 2 study: CEP-701 in relapsed AML
- Phase 2 study: AS1411 in relapsed AML
- Phase 2 study: Midostaurin in systemic mastocytosis
- Phase 2/3 study: AZD1152 in older AML
- Phase 3 study: PKC412 in AML
- Phase 3 study: Amonafide in secondary AML
- Phase 3 study: Elacytarabine in relapsed AML
- Phase 3: Voreloxin in relapsed AML
- Phase 1: KB004 in advanced haematological malignancies
- Phase 1: Meisoindigo in AML unfit for chemotherapy
Research area keywords
- Acute myeloid leukaemia
- Azacytidine
- BH3
- Bcl-2
- Lenalidomide
- Leukaemia Foundation
- Leukemia
- Lymphoma
- Mcl-1
- Relapse and refractory
- Research Fellow
- Victorian Cancer Agency
- clinical AML
- leukaemic stem cells
- translational AML
Network
Recent external collaboration on country level. Dive into details by clicking on the dots or
Projects
-
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.
Wei, A. & Kennedy, N.
2/12/20 → 31/12/25
Project: Research
-
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukaemia.
Wei, A., Bajel, A. & Kennedy, N.
20/10/20 → 31/12/25
Project: Research
-
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy.
Wei, A. & Kennedy, N.
6/10/20 → 31/12/25
Project: Research
-
Phase I/II, international, multicentre, open-label, non-randomised, non-comparative, study evaluating the safety, tolerability and clinical activity of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with azacitidine in patients with acute myeloid leukaemia (AML).
Wei, A. & Kennedy, N.
6/10/20 → 31/12/25
Project: Research
-
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome.
Wei, A., Kennedy, N., Kenealy, M., Forsyth, C. J., Shortt, J., Hertzberg, M. S., Bajel, A., Kwan, J., Campbell, P., Beligaswatte, A., Taylor, K., Stevenson, W. S., Hiwase, D. K. & Walker, P. A.
1/09/20 → 31/12/25
Project: Research
Research output
-
Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells
McManus, J. F., Nguyen, N. Y. N., Davey, R. A., MacLean, H. E., Pomilio, G., McCormack, M. P., Chiu, W. S., Wei, A. H., Zajac, J. D. & Curtis, D. J., 20 Apr 2020, (Accepted/In press) In : European Journal of Haematology. 8 p.Research output: Contribution to journal › Article › Research › peer-review
-
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
Chua, C. C., Roberts, A. W., Reynolds, J., Fong, C. Y., Ting, S. B., Salmon, J. M., MacRaild, S., Ivey, A., Tiong, I. S., Fleming, S., Brown, F. C., Loo, S., Majewski, I. J., Bohlander, S. K. & Wei, A. H., 20 Oct 2020, In : Journal of Clinical Oncology. 38, 30, p. 3506-3517 12 p.Research output: Contribution to journal › Article › Research › peer-review
8 Citations (Scopus) -
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
DiNardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., Glytsou, C., Fleming, S. A., Zhang, Q., Ma, H., Patel, K. P., Kornblau, S. M., Xu, Z., Chua, C. C., Chen, X., Blombery, P. & 9 others, , 12 Mar 2020, In : Blood. 135, 11, p. 791-803 13 p.Research output: Contribution to journal › Article › Research › peer-review
46 Citations (Scopus) -
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML
Brown, A. L., Arts, P., Carmichael, C. L., Babic, M., Dobbins, J., Chong, C. E., Schreiber, A. W., Feng, J., Phillips, K., Wang, P. P. S., Ha, T., Homan, C. C., King-Smith, S. L., Rawlings, L., Vakulin, C., Dubowsky, A., Burdett, J., Moore, S., McKavanagh, G., Henry, D. & 39 others, , 24 Mar 2020, In : Blood Advances. 4, 6, p. 1131-1144 14 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile10 Citations (Scopus) -
BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals
Srivastava, R., Cao, Z., Nedeva, C., Naim, S., Bachmann, D., Rabachini, T., Gangoda, L., Shahi, S., Glab, J., Menassa, J., Osellame, L., Nelson, T., Fernandez-Marrero, Y., Brown, F., Wei, A., Ke, F., O'Reilly, L., Doerflinger, M., Allison, C., Kueh, A. & 5 others, , 30 Jul 2019, In : Proceedings of the National Academy of Sciences of the United States of America. 116, 31, p. 15469-15474 6 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile11 Citations (Scopus)
Prizes
-
2003: Albert Baikie Award, Best Oral Abstract Presentation, Haematology Society of Australia
Wei, Andrew (Recipient), 2004
Prize: Prize (including medals and awards)
-
2003: Young Investigator Award, Best Oral Abstract Presentation, Annual Scientific Meeting, Hobart
Wei, Andrew (Recipient), 2003
Prize: Prize (including medals and awards)
-
2004: New Investigator Award, Best Oral Abstract, Annual Scientific Meeting, Canberra
Wei, Andrew (Recipient), 2004
Prize: Prize (including medals and awards)
Activities
- 8 Membership of an advisory panel/policy group/ board
-
AMERICAN SOCIETY OF HAEMATOLOGY (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
HAEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
Royal College of Pathologists of Australasia (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
The Royal Australasian College of Physicians (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
EUROPEAN HAEMATOLOGY ASSOCIATION (External organisation)
Andrew Wei (Member)
1 Jan 2012Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board